CN103536652A - 冬凌草叶水提物的纳米结构及应用 - Google Patents
冬凌草叶水提物的纳米结构及应用 Download PDFInfo
- Publication number
- CN103536652A CN103536652A CN201210236269.0A CN201210236269A CN103536652A CN 103536652 A CN103536652 A CN 103536652A CN 201210236269 A CN201210236269 A CN 201210236269A CN 103536652 A CN103536652 A CN 103536652A
- Authority
- CN
- China
- Prior art keywords
- water extract
- rabdosia rubescens
- rubescens leaf
- leaf
- nanosphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 239000000284 extract Substances 0.000 title claims abstract description 58
- 230000000694 effects Effects 0.000 claims abstract description 10
- 230000003262 anti-osteoporosis Effects 0.000 claims abstract description 9
- 239000007864 aqueous solution Substances 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 5
- 241001646826 Isodon rubescens Species 0.000 claims description 58
- 238000001914 filtration Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000008399 tap water Substances 0.000 claims description 2
- 235000020679 tap water Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims 1
- 239000012153 distilled water Substances 0.000 abstract description 3
- 239000002077 nanosphere Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 229910021642 ultra pure water Inorganic materials 0.000 description 9
- 239000012498 ultrapure water Substances 0.000 description 9
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 6
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007965 phenolic acids Chemical class 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- -1 acyl tartaric acid Chemical compound 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 2
- SWGKAHCIOQPKFW-JTNORFRNSA-N Caftaric acid Chemical compound OC(=O)[C@H](O)[C@H](C(O)=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 SWGKAHCIOQPKFW-JTNORFRNSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 2
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- SWGKAHCIOQPKFW-GHMZBOCLSA-N caffeoyltartaric acid Natural products OC(=O)[C@H](O)[C@H](C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 SWGKAHCIOQPKFW-GHMZBOCLSA-N 0.000 description 2
- VOXZDWNPVJITMN-WKUFJEKOSA-N estradiol group Chemical group [C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- 150000000307 17β-estradiols Chemical class 0.000 description 1
- DLBZXSBRTZLLKR-OWOJBTEDSA-N 2-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enyl]-2,3-dihydroxybutanedioic acid Chemical class OC(=O)C(O)C(O)(C(O)=O)C\C=C\C1=CC=C(O)C(O)=C1 DLBZXSBRTZLLKR-OWOJBTEDSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- BLANPKHHDVIMSA-UHFFFAOYSA-N 4-(1h-indol-5-yl)oxan-4-ol Chemical compound C=1C=C2NC=CC2=CC=1C1(O)CCOCC1 BLANPKHHDVIMSA-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001183967 Isodon Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229930016920 cichoric acid Natural products 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 description 1
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- PMKQSEYPLQIEAY-UHFFFAOYSA-N trans-caffeoyl-L-malic acid Natural products OC(=O)CC(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 PMKQSEYPLQIEAY-UHFFFAOYSA-N 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及冬凌草叶用蒸馏水80℃提取制备水提物、涉及该水提物浓缩得到的固体在水溶液中的纳米结构、进一步涉及纳米结构对抗骨质疏松活性的影响。
Description
发明领域
本发明涉及冬凌草叶用蒸馏水80 oC提取制备水提物、涉及该水提物浓缩得到的固体在水溶液中的纳米结构、进一步涉及纳米结构对抗骨质疏松活性的影响。本发明属于生物医药领域。
背景技术
冬凌草(DLC)，是唇形科香茶菜属植物碎米桠 Rabdosia rubescens (Hemsl.) Hara 的全草。冬凌草为多年生草本植物，广泛分布于我国黄河长江流域，主产于河南济源太行山、王屋山区一带。因具有清热解毒、清咽利喉和消肿止痛功能， 民间常年将冬凌草叶当作茶叶煮水饮用。在过去的30多年里，冬凌草的化学成分及药理作用研究主要集中在叶的脂溶性部分，代表性成分为冬凌草甲素和冬凌草乙素。通过长期研究积累，发明人披露了冬凌草叶水提物的21种酚酸。它们是单咖啡酰酒石酸, 丹参素, 丹参素咖啡酰酒石酸, 2-绿原酸-3-对羟基桂皮酸酒石酸酯, 单阿魏酰酒石酸, 绿原酸, 咖啡酰苹果酸, 二咖啡酰酒石酸, 迷迭香酰丹参素酒石酸酯, yuannaneic acid E, 紫草酸, 咖啡酸, 咖啡酰对羟基桂皮酰酒石酸, 氢化紫草酸。2-丹参素-3-乙酰莽草酸酒石酸酯, 丹参素咖啡酰酒石酸, 2-(丙二酰奎尼酸单酯)-3-丹参素酒石酸奎尼酸单酯, 水化丹酚酸B, 丹参素酰丹参素酰迷迭香酸酯, 丹酚酸B和迷迭香酸。这些酚酸在冬凌草叶水提物中的相对含量接近83%。应当指出的是，到目前为止还没有任何与冬凌草叶水提物纳米结构的报道。
通过长期研究积累，发明人认识到这些酚酸在水溶液中可以通过π-π相互作用，氢键相互作用和疏水性相互作用发生共组装，形成纳米结构。恰恰是这些酚酸在水溶液中共组装形成的纳米结构，使得冬凌草叶水提物显示重要的生物活性。根据这些认识，发明人提出了本发明。
发明内容
本发明的第一个内容是提供冬凌草叶水提物。
本发明的第二个内容是测定冬凌草叶水提物的纳米结构。
本发明的第三个内容是阐明冬凌草叶水提物的纳米结构与抗骨质疏松活性的关系。
附图说明
图1在浓度为 78.75 mg/ml的超纯水溶液中，冬凌草叶的水提物以直径为102.3 nm的纳米球的聚集体存在。
图2在浓度为 15.75 mg/ml的超纯水溶液中冬凌草茎的水提物以直径为46.4-110.7 nm的纳米球存在。
图3在浓度为 3.15 mg/ml的超纯水溶液中冬凌草茎的水提物以直径为58.8-147.1 nm的纳米球存在。
图4在浓度为 0.63 mg/ml的超纯水溶液中冬凌草叶的水提物以直径为81.8-218.2 nm的纳米球存在。
具体实施方式
为了进一步阐述本发明,下面给出一系列实施例。这些实施例完全是例证性的,它们仅用来对本发明进行具体描述,不应当理解为对本发明的限制。
实施例1 冬凌草叶水提物的制备
21 g干冬凌草叶自来水洗净之后加500 ml双蒸水于60 - 100 oC, 优选80 oC搅拌提取10 - 60分钟, 优选30分钟。过滤得到的清液于40 oC减压浓缩, 得到6.3 g 冬凌草叶水提物, 为淡黄色固体, 研成粉末, 供后面的研究使用。
实施例2 冬凌草叶水提物的纳米结构
为了描述冬凌草叶水提物的纳米结构，本发明将冬凌草叶水提物的淡黄色固体配成浓度为 78.75 mg/ml, 15.75 mg/ml, 3.15 mg/ml 和 0.63 mg/ml的超纯水溶液，然后将溶液滴在铜网上，35 °C挥发 24 h至干溶后按标准操作(20 eV 能量窗口，6000 - 400,000倍) 在透射电镜 (JSM- 6360 LV, JEOL, Tokyo, Japan)下观察纳米形态。测定的透射电镜照片显示在图1 – 4中。
图1说明在浓度为 78.75 mg/ml的超纯水溶液中，冬凌草叶的水提物以直径为102.3 nm的纳米球的聚集体存在。
图2说明在浓度为 15.75 mg/ml的超纯水溶液中，冬凌草叶的水提物以直径为46.4-110.7 nm的纳米球存在。
图3说明在浓度为3.15 mg/ml的超纯水溶液中，冬凌草叶的水提物以直径为58.8-147.1 nm的纳米球存在。
图4说明在浓度为0.63 mg/ml的超纯水溶液中，冬凌草叶的水提物以直径为81.8-218.2 nm的纳米球存在。
图2-4说明当浓度从15.75 mg/ml降至3.15 mg/ml再降至0.63 mg/ml时，冬凌草叶的水提物形成的纳米球的直径逐步增大。这种现象揭示，我们可以通过控制冬凌草叶的水提物的浓度来控制冬凌草叶的水提物形成的纳米球的直径。图1-2说明当浓度从 78.75 mg/ml降至15.75 mg/ml时，不仅冬凌草叶的水提物形成的纳米球的直径减小，而且纳米球的聚集体也不再存在。这种现象同样揭示，我们可以通过控制冬凌草叶的水提物的浓度来控制冬凌草叶的水提物形成的纳米球的直径和聚集状态。
实施例 3 冬凌草叶水提物的抗骨质疏松活性评价
5周龄ICR小鼠，体重25.7±2.1g, 48只随机分组，即卵巢切除组＋生理盐水 (称生理盐水组)、假手术组＋生理盐水 (称假手术组)、卵巢切除＋17β-雌二醇 (称雌二醇组)、卵巢切除＋冬凌草叶水提物 (称DLC组)。
用2%戊巴比妥钠按40 mg/kg剂量腹腔注射，麻醉小鼠，剪开小鼠腹腔，找到两侧的输卵管，在两侧输卵管的盲端找到卵巢，去除小鼠双侧卵巢，结扎输卵管(手术过程中如果小鼠苏醒过来，则用棉花蘸取适量无水乙醚置于小鼠的鼻子处使之麻醉)。结扎好后，滴加几滴青霉素至小鼠腹腔，再将小鼠腹腔缝合好，于伤口外面涂上适量0.1%苯扎溴铵消毒液，以避免伤口感染。
术后5天开始口服给药。卵巢切除组和假手术组小鼠每天口服0.2 ml生理盐水。雌二醇组小鼠每天口服0.2 ml 17β-雌二醇的生理盐水溶液, 剂量为30 μg/kg。冬凌草叶水提物组小鼠每天口服0.2 ml冬凌草叶水提物的生理盐水溶液, 剂量为5 mg/kg, 25 mg/kg, 125 mg/kg和625 mg/kg。给药四周后用骨密度仪对小鼠股骨关节头下方0.2 - 0.4 mm 处进行定量断断层扫描，得到骨矿物质密度 (表4及图4)、称体重、处死、分离小鼠的肺、肝、脾、子宫，得它们的净重 (表5)。取小鼠左侧股骨、剔除干净肌肉组织、用氯仿:甲醇(2:1)浸泡两次（每次3小时）脱脂、置120 oC烘箱中烘6小时称干重、置800 o马福炉煅烧8小时称灰重、计算灰重与干重的比值(g/g)得骨矿含量 (表1)。
表1 口服冬凌草叶水提物对小鼠骨密度的影响
n=10; a) 与卵巢切除 + 生理盐水组，卵巢切除＋17β-雌二醇组, 5 mg/kg冬凌草叶水提物组，25 mg/kg冬凌草叶水提物组及625 mg/kg冬凌草叶水提物组比 p < 0.01，与假手术 + 生理盐水组比p > 0.05; b) 与卵巢切除 + 生理盐水组, 卵巢切除＋17β-雌二醇组及5 mg/kg冬凌草叶水提物组比 p < 0.05; c) 与卵巢切除 + 生理盐水组比 p < 0.05, 与卵巢切除＋17β-雌二醇组比p > 0.05; d) 与卵巢切除 + 生理盐水组, 卵巢切除＋17β-雌二醇组及5 mg/kg冬凌草叶水提物组比 p < 0.05, 与25 mg/kg冬凌草叶水提物组比p > 0.05.
实施例4 冬凌草茎水提物的纳米结构与抗骨质疏松活性的关系
实施例2揭示，当浓度从15.75 mg/ml降至3.15 mg/ml 再降至0.63 mg/ml时，冬凌草叶的水提物形成的纳米球的直径逐步增大。当浓度从78.75 mg/ml降至15.75 mg/ml时，冬凌草茎的水提物形成的纳米球的直径反而减小。浓度为78.75 mg/ml时冬凌草茎的水提物形成的纳米球发生聚集。按照每只小鼠的血量为2 ml估算，给药剂量为625 mg/kg, 125 mg/kg, 25 mg/kg和5 mg/kg时的血药浓度分别为78.75 mg/ml, 15.75 mg/ml, 3.15 mg/ml 和 0.63 mg/ml。这种估算说明，冬凌草叶的水提物形成的纳米球的直径在46.4-110.7 nm时，抗骨质疏松活性最好。冬凌草叶的水提物形成的纳米球的直径在大于200 nm时，抗骨质疏松活性变差。此外，当直径为100 nm左右的纳米球发生聚集时，抗骨质疏松活性也不理想。的因为冬凌草叶的水提物形成的纳米球的直径紧密依赖于浓度，所以我们可以通过浓度-粒径-活性三者的关系来谋取理想的疗效。这就是冬凌草叶水提物的纳米结构的应用价值。
Claims (3)
1. 冬凌草叶水提物的制备工艺，该工艺包括将干冬凌草叶自来水洗净之后按1:24的比例加水于60 - 100 oC, 优选80 oC搅拌提取10 - 60分钟, 优选30分钟，过滤得到的清液于40 oC减压浓缩, 得到冬凌草叶水提物干粉, 为淡黄色固体。
2. 冬凌草叶水提物在水溶液中的纳米结构。
3. 冬凌草茎水提物在水溶液中的纳米结构对抗骨质疏松活性的影响。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210236269.0A CN103536652A (zh) | 2012-07-10 | 2012-07-10 | 冬凌草叶水提物的纳米结构及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210236269.0A CN103536652A (zh) | 2012-07-10 | 2012-07-10 | 冬凌草叶水提物的纳米结构及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103536652A true CN103536652A (zh) | 2014-01-29 |
Family
ID=49960766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210236269.0A Pending CN103536652A (zh) | 2012-07-10 | 2012-07-10 | 冬凌草叶水提物的纳米结构及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103536652A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108926525A (zh) * | 2018-09-14 | 2018-12-04 | 南方医科大学 | 一种关节炎外用透皮吸收制剂 |
| CN112402407A (zh) * | 2020-11-06 | 2021-02-26 | 北京恒润泰生医药科技有限公司 | 冬凌草叶水提物粉末、其制备、治疗肺纤维化作用及应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001278802A (ja) * | 2000-03-30 | 2001-10-10 | Hiroyuki Sumi | 血栓予防剤 |
| CN101167509A (zh) * | 2006-10-25 | 2008-04-30 | 张海 | 冬凌草茶的制造方法 |
| CN102908285A (zh) * | 2012-10-23 | 2013-02-06 | 安徽省王巢食品有限公司 | 一种纯天然蜂王浆增白祛斑花粉膏及其生产方法 |
-
2012
- 2012-07-10 CN CN201210236269.0A patent/CN103536652A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001278802A (ja) * | 2000-03-30 | 2001-10-10 | Hiroyuki Sumi | 血栓予防剤 |
| CN101167509A (zh) * | 2006-10-25 | 2008-04-30 | 张海 | 冬凌草茶的制造方法 |
| CN102908285A (zh) * | 2012-10-23 | 2013-02-06 | 安徽省王巢食品有限公司 | 一种纯天然蜂王浆增白祛斑花粉膏及其生产方法 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108926525A (zh) * | 2018-09-14 | 2018-12-04 | 南方医科大学 | 一种关节炎外用透皮吸收制剂 |
| CN108926525B (zh) * | 2018-09-14 | 2021-08-31 | 南方医科大学 | 一种关节炎外用透皮吸收制剂 |
| CN112402407A (zh) * | 2020-11-06 | 2021-02-26 | 北京恒润泰生医药科技有限公司 | 冬凌草叶水提物粉末、其制备、治疗肺纤维化作用及应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Adam et al. | Diuretic properties of Orthosiphon stamineus Benth | |
| CN101167529A (zh) | 中草药复合饲料添加剂 | |
| CN102247420A (zh) | 一种墨旱莲提取物的制备方法及用途 | |
| CN108392591B (zh) | 一种可预防阴道炎的纳米银女士抑菌平衡凝胶 | |
| CN104013682A (zh) | 一种抑制藤黄微球菌的中药抑菌组合物 | |
| CN101953980B (zh) | 采用豁痰泄浊法治疗慢性阻塞性肺疾病的薤葶合剂 | |
| CN103623248B (zh) | 一种降压中药组合物 | |
| CN103536652A (zh) | 冬凌草叶水提物的纳米结构及应用 | |
| Du et al. | The modulation of gut microbiota by herbal medicine to alleviate diabetic kidney disease–A review | |
| CN103479856A (zh) | 知母化学成分群提取物及其制备工艺 | |
| CN200994863Y (zh) | 含有茶籽精华素的保健纸尿裤 | |
| CN101099787A (zh) | 一种具有显著广谱抗病毒作用的中药组合物 | |
| CN104771702A (zh) | 一种治疗脂肪肝和脂肪性肝炎的中药组合物的制备方法 | |
| CN104524341B (zh) | 一种清咽颗粒及其制备方法 | |
| CN103505395B (zh) | 一种连翘叶中药牙膏 | |
| CN103655301B (zh) | 一种含有一枝蒿提取物的牙膏及其制备方法 | |
| CN108478500B (zh) | 一种用于口腔的组合物及其应用 | |
| CN104083789A (zh) | 一种抗菌杀毒复合型空气清新剂 | |
| CN103536651A (zh) | 冬凌草茎水提物的纳米结构及应用 | |
| CN104771745A (zh) | 一种治疗腹泻的中药组合物及其制备方法和应用 | |
| CN103169762A (zh) | 一种用于增强动物免疫力的药物 | |
| CN111249192A (zh) | 一种清新口气、抑菌抗炎的中草药牙膏组合及其制备方法 | |
| CN101104045A (zh) | 一种治疗甲状腺病的中药 | |
| CN113599313A (zh) | 抑菌洗手液 | |
| CN106691956A (zh) | 一种消炎抑菌漱口水 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150925 Address after: 100088, Beijing, Zhichun Road, Haidian District 51 Shen Chang building, room 5373, room 5 Applicant after: BEIJING YISHENG KANGHUA PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: The 100069 Beijing Fengtai District right outside the West No. 10 Applicant before: Peng Li |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140129 |